Heartware International, (FRA:HIY1) Debt-to-Equity : 1.14 (As of Jun. 2016)

View and export this data going back to . Start your Free Trial

What is Heartware International, Debt-to-Equity?

Heartware International,'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2016 was €0.0 Mil. Heartware International,'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2016 was €171.0 Mil. Heartware International,'s Total Stockholders Equity for the quarter that ended in Jun. 2016 was €150.7 Mil. Heartware International,'s debt to equity for the quarter that ended in Jun. 2016 was 1.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Heartware International,'s Debt-to-Equity or its related term are showing as below:

FRA:HIY1' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: 1.14

FRA:HIY1's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs FRA:HIY1: 1.14

Heartware International, Debt-to-Equity Historical Data

The historical data trend for Heartware International,'s Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heartware International, Debt-to-Equity Chart

Heartware International, Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Debt-to-Equity

Get a 7-Day Free Trial

0.74

1.47

0.54

0.55

1.01

Heartware International, Quarterly Data
	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Debt-to-Equity	Get a 7-Day Free Trial															0.90	1.02	1.01	1.08	1.14

Competitive Comparison of Heartware International,'s Debt-to-Equity

For the Medical Devices subindustry, Heartware International,'s Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heartware International,'s Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Heartware International,'s Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Heartware International,'s Debt-to-Equity falls into.

Heartware International, Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Heartware International,'s Debt to Equity Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	175.395)	/	173.036
	=	1.01

Heartware International,'s Debt to Equity Ratio for the quarter that ended in Jun. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	170.975)	/	150.67
	=	1.13

Heartware International, (FRA:HIY1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Heartware International, Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Heartware International,'s Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Heartware International, (FRA:HIY1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heartware International, Inc. (FRA:HIY1) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.heartware.com

Heartware International Inc was incorporated in Delaware on July 29, 2008 and became the successor issuer to HeartWare Limited, an Australian corporation, on November 13, 2008, as a result of the Australian Court approved redomiciliation of HeartWare Limited from Australia to Delaware. HeartWare is a medical device company engaged in developing implantable blood pumps for the treatment of advanced heart failure. The Company operates one reportable segment which includes the design, manufacture and marketing of medical devices for the treatment of advanced heart failure. The HeartWare Ventricular Assist System, which includes a left ventricular assist device, or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients with advanced heart failure. Beyond the HeartWare System, the company is also evaluating its next device, the Miniaturized Ventricular Assist Device. The MVAD is based on the same technology platform as the HeartWare System but adopts an axial flow, rather than a centrifugal flow, configuration and is being developed in multiple configurations. The MVAD designs are currently at the preclinical stage and undergoing animal studies focused on minimally invasive implantation techniques and are each approximately one-third the size of the HVAD Pump. The Company's competitors in the implantable cardiac assist space include Thoratec Corporation, Jarvik Heart, Inc., MicroMed Cardiovascular, Berlin Heart GmbH, and Sunshine Heart, Inc. HEARTWARE, HVAD, MVAD, PAL, CIRCULITE, SYNERGY and various company logos are the trademarks of the Company, in the United States, Europe, Australia and other countries.

Heartware International, (FRA:HIY1) Headlines

No Headlines